R. Spencer, R. Scholl, and N. Erbay, Références bibliographiques 1 Tc-99m Pertechnetate Thyroid Images in Hyperthyroidism: Size, Distribution, and Presence of a Pyramidal Lobe, Clinical Nuclear Medicine, issue.48, pp.22-519, 1997.

J. E. Arnold and S. Pinsky, Comparison of 99m Tc and 123 I for Thyroid Imaging, Journal of Nuclear Medicine, vol.17, issue.4, pp.261-267, 1976.

H. Iida, Absolute quantitation of myocardial blood flow with 201Tl and dynamic SPECT in canine: optimisation and validation of kinetic modelling, European Journal of Nuclear Medicine and Molecular Imaging, vol.36, issue.7, pp.896-905, 2008.
DOI : 10.1007/BF00181062

H. Hanyu, The progression of cognitive deterioration and regional cerebral blood flow patterns in Alzheimer's disease: A longitudinal SPECT study, Journal of the Neurological Sciences, vol.290, issue.1-2, pp.96-101, 2010.
DOI : 10.1016/j.jns.2009.10.022

A. Stoessl, Neuroimaging in Parkinson???s Disease, Neurotherapeutics, vol.70, issue.Suppl 1, pp.72-81, 2011.
DOI : 10.1007/s13311-010-0007-z

F. Cachin, A. Kelly, and J. Maublant, Evaluation de la réponse thérapeutique en cancérologie: place de l'imagerie isotopique, Bull Cancer, issue.93, p.1191, 2006.

D. F. Wong, Imaging in Drug Discovery, Preclinical, and Early Clinical Development, J Nucl Med, vol.49, issue.6, pp.26-28, 2008.

D. Hwang and J. Evelhoch, How the Biopharmaceutical Industry Uses Molecular Imaging, J Nucl Med, vol.49, issue.6, pp.24-25, 2008.

S. Supiot, Le point sur??les??avanc??es r??centes de??la??radio-immunoth??rapie alpha, Cancer/Radioth??rapie, vol.11, issue.5, pp.252-259, 2007.
DOI : 10.1016/j.canrad.2007.05.001

D. M. Gadbois, Alterations in the Progression of Cells through the Cell Cycle after Exposure to Alpha Particles or Gamma Rays, Radiation Research, vol.146, issue.4, pp.414-424, 1996.
DOI : 10.2307/3579303

M. R. Zalutsky and O. R. Pozzi, Radioimmunotherapy with alpha-emitting radionuclides, The Quarterly Journal of Medicine and Molecular Imaging, issue.48, p.289, 2004.

D. A. Mulford, D. A. Scheinberg, and J. G. Jurcic, The Promise of Targeted !-Particle Therapy, J Nucl Med, pp.46-199, 2005.

M. T. Ercan and M. Caglar, Therapeutic radiopharmaceuticals, Current Pharmaceutical Design, issue.611, p.1085, 2000.

J. G. Jurcic, Targeted ! particle immunotherapy for myeloid leukemia, Blood, vol.100, issue.4, pp.1233-1239, 2002.

M. Salvatori, L. Indovina, and L. Mansi, Targeted alpha-Particle Therapy: A Clinical Overview. current radiopharmaceuticals, pp.251-253, 2008.

S. Nilsson, Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study, Chapitre I : Introduction bibliographique 64 16, pp.587-594, 2007.
DOI : 10.1016/S1470-2045(07)70147-X

S. Nilsson, First Clinical Experience with ??-Emitting Radium-223 in the Treatment of Skeletal Metastases, Clinical Cancer Research, vol.11, issue.12, pp.4451-4459, 2005.
DOI : 10.1158/1078-0432.CCR-04-2244

M. R. Zalutsky, Clinical Experience with ??-Particle Emitting 211At: Treatment of Recurrent Brain Tumor Patients with 211At-Labeled Chimeric Antitenascin Monoclonal Antibody 81C6, Journal of Nuclear Medicine, vol.49, issue.1, pp.30-38, 2008.
DOI : 10.2967/jnumed.107.046938

M. E. Lam, J. H. Klerk, and P. Rijk, Re-HEDP for metastatic bone pain in breast cancer patients, European Journal of Nuclear Medicine and Molecular Imaging, issue.0, pp.31-162, 2004.

W. A. Volkert, T. J. Hoffman, and T. Radiopharmaceuticals, Therapeutic Radiopharmaceuticals, Chemical Reviews, vol.99, issue.9, pp.2269-2292, 1999.
DOI : 10.1021/cr9804386

M. D. Bartholomä, Technetium and Gallium Derived Radiopharmaceuticals: Comparing and Contrasting the Chemistry of Two Important Radiometals for the Molecular Imaging Era, Chemical Reviews, vol.110, issue.5, pp.2903-2920, 2010.
DOI : 10.1021/cr1000755

N. Watanabe, Molecular Therapy of Human Neuroblastoma Cells Using Auger Electrons of 111 In-Labeled N-myc Antisense Oligonucleotides, J Nucl Med, issue.10, pp.47-1670, 2006.

A. I. Kassis and S. J. Adelstein, Radiobiologic Principles in Radionuclide Therapy, J Nucl Med, vol.46, pp.4-12, 2005.

J. A. Donoghue and T. E. Wheldon, Targeted radiotherapy using Auger electron emitters, Physics in Medicine and Biology, issue.10, p.41, 1973.

G. A. Alexiou, The Value of 99m Tc-Tetrofosmin Brain SPECT in Predicting Survival in Patients with Glioblastoma Multiforme, J Nucl Med, issue.12, pp.51-1923, 2010.

W. Duvall, Reduced isotope dose and imaging time with a high-efficiency CZT SPECT camera, Journal of Nuclear Cardiology, vol.30, issue.5, pp.1-11, 2011.
DOI : 10.1007/s12350-011-9379-7

W. Duvall, Comparison of high efficiency CZT SPECT MPI to coronary angiography, Journal of Nuclear Cardiology, vol.11, issue.4, pp.595-604, 2011.
DOI : 10.1007/s12350-011-9382-z

K. Strobel, P. Veit-hailbach, and T. F. Hany, Utilisation judicieuse du PET/CT en oncologie, Forum Med Suisse, issue.7, pp.270-277, 2007.

M. P. Dunphy and J. S. Lewis, Radiopharmaceuticals in Preclinical and Clinical Development for Monitoring of Therapy with PET, Journal of Nuclear Medicine, vol.50, issue.Suppl_1, pp.50-106, 2009.
DOI : 10.2967/jnumed.108.057281

!. Kubí and V. C. Ek, Gallium(III) Complexes of DOTA and DOTA!Monoamide: Kinetic and Thermodynamic Studies, Inorganic Chemistry, issue.23, pp.49-10960, 2010.

K. Plössl, A novel gallium bisaminothiolate complex as a myocardial perfusion imaging agent, Nuclear Medicine and Biology, vol.35, issue.1, pp.83-90, 2008.
DOI : 10.1016/j.nucmedbio.2007.08.002

E. Boros, Ga PET Imaging Agent Elaboration, Journal of the American Chemical Society, vol.132, issue.44, pp.15726-15733, 2010.
DOI : 10.1021/ja106399h

K. L. Parthasarathy and E. S. Crawford, Treatment of Thyroid Carcinoma: Emphasis on High-Dose 131 I Outpatient Therapy, Journal of Nuclear Medicine Technology, vol.30, issue.4, pp.165-171, 2002.

K. Liepe, Radiosynovectomy using yttrium-90, phosphorus-32 or rhenium-188 radiocolloids versus corticoid instillation for rheumatoid arthritis of the knee, Annals of Nuclear Medicine, vol.32, issue.5, pp.317-323, 2011.
DOI : 10.1007/s12149-011-0467-1

B. Das, Role of radiosynovectomy in the treatment of rheumatoid arthritis and hemophilic arthropathies, Biomedical Imaging and Intervention Journal, vol.3, issue.4, p.1, 2007.
DOI : 10.2349/biij.3.4.e45

P. A. Schubiger, R. Alberto, and A. Smith, Vehicles, Chelators, and Radionuclides:?? Choosing the ???Building Blocks??? of an Effective Therapeutic Radioimmunoconjugate, Bioconjugate Chemistry, vol.7, issue.2, pp.165-179, 1996.
DOI : 10.1021/bc950097s

A. C. Perkins, In vivo molecular targeted radiotherapy, Biomedical Imaging and Intervention Journal, issue.2, 2005.

E. Garcïa-garayoa, R. Schibli, and P. A. Schubiger, Peptides radiolabeled with Re- 186/188 and Tc-99m as potential diagnostic and therapeutic agents. Nuclear Science and Techniques, pp.88-100, 2007.

A. Bao, 186 Re-Liposome Labeling Using 186 Re-SNS/S Complexes: In Vitro Stability, Imaging, and Biodistribution in Rats, J Nucl Med, issue.12, pp.44-1992, 2003.

N. D. Papathanasiou, 18 F-FDG PET/CT and 123 I-Metaiodobenzylguanidine Imaging in High-Risk Neuroblastoma: Diagnostic Comparison and Survival Analysis

N. Tsuyuguchi, Evaluation of Pleomorphic Xanthoastrocytoma by Use of Positron Emission Tomography with [ 18 F]-Fluorodeoxyglucose and [ 11 C]-Methionine Tracers, AJNR Am J Neuroradiol, vol.22, issue.2, pp.311-313, 2001.

B. Kang, 18 F-FDG and 11 C-MET Positron Emission Tomography Findings of Cutaneous Mast Cell Tumor in a Dog, Journal of Veterinary Medical Science, issue.3, pp.73-355, 2011.

C. Shiue, C. D. Arnett, and A. P. Wolf, Synthesis and biodistribution of 2-deoxy-2- [ 18 F]fluoro-d-glucopyranosyl [ 18 F]fluoride in mice, European Journal of Nuclear Medicine and Molecular Imaging, issue.92, pp.77-80, 1984.

B. Långström, Synthesis of L-and D-[Methyl-11 C]Methionine, Chapitre I : Introduction bibliographique 66 45, pp.28-1037, 1987.

R. K. Hom and J. A. Katzenellenbogen, Synthesis of a Tetradentate Oxorhenium(V) Complex Mimic of a Steroidal Estrogen, The Journal of Organic Chemistry, vol.62, issue.18, pp.62-6290, 1997.
DOI : 10.1021/jo970471c

D. Y. Chi, Homodimeric and Heterodimeric Bis(amino thiol) Oxometal Complexes with Rhenium(V) and Technetium(V). Control of Heterodimeric Complex Formation and an Approach to Metal Complexes that Mimic Steroid Hormones, Journal of Medicinal Chemistry, vol.37, issue.7, pp.37-928, 1994.
DOI : 10.1021/jm00033a010

Y. Fu, Characterization of the adrenomedullin receptor acting as the target of a nez radiopharmaceutical biomolecule for lung imaging, European journal of pharmacology, pp.617-118, 2009.

D. Goldenberg, Carcinoembryonic antigen immunoscintigraphy complements mammography in the diagnosis of breast carcinoma, Cancer, vol.39, issue.1, pp.104-115, 2000.
DOI : 10.1002/1097-0142(20000701)89:1<104::AID-CNCR15>3.0.CO;2-E

C. R. Dias, Tc-99m direct radiolabeling of monoclonal antibody ior egf/r3: quality control and image studies in mice, Brazilian Archives of Biology and Technology, vol.48, issue.spe2, pp.29-35, 2005.
DOI : 10.1590/S1516-89132005000700004

E. John, Technetium-99m-Labeled Monoclonal Antibodies: Influence of Technetium-99m Binding Sites, Journal of Nuclear Medicine, vol.35, issue.5, pp.876-881, 1994.

M. F. Giblin, Design and characterization of ??-melanotropin peptide analogs cyclized through rhenium and technetium metal coordination, Proceedings of the National Academy of Sciences, pp.95-12814, 1998.
DOI : 10.1073/pnas.95.22.12814

M. Aufort, Synthesis and biochemical evaluation of a cyclic RGD oxorhenium complex as new ligand of ??V??3 integrin, European Journal of Medicinal Chemistry, vol.44, issue.9, pp.3394-3401, 2009.
DOI : 10.1016/j.ejmech.2009.02.022

M. Aufort, Synthesis, in vitro screening and in vivo evaluation of cyclic RGD analogs cyclized through oxorhenium and oxotechnetium coordination, European Journal of Medicinal Chemistry, vol.46, issue.5, pp.1779-1788, 2011.
DOI : 10.1016/j.ejmech.2011.02.032

C. Clavaud, Combinatorial Self-Assembly of Cyclophilin hCyp-18 Ligands through Rhenium Coordination, ChemBioChem, vol.97, issue.9, pp.1352-1355, 2006.
DOI : 10.1002/cbic.200600204

C. Clavaud, Dynamic Combinatorial Self???Assembly of Cyclophilin hCyp???18 Ligands through Oxorhenium Coordination, ChemBioChem, vol.27, issue.11, pp.1823-1829, 2008.
DOI : 10.1002/cbic.200800187

C. Clavaud, Cyclic and Acyclic Oxorhenium(V)???Peptide Conjugates as New Ligands of the Human Cyclophilin hCyp-18, Bioconjugate Chemistry, vol.17, issue.3, pp.807-814, 2006.
DOI : 10.1021/bc050329f

G. Fragasso, High prevalence of 99m tc-tetrofosmin reverse perfusion pattern in patients with myocardial infarction and angiographically smooth coronary arteries. 72 Nuclear Medicine and Infection Detection: The Relative Effectiveness of Imaging with 111 In-Oxine-, 99m Tc-HMPAO-, and 99m Tc-Stannous Fluoride Colloid- Labeled Leukocytes and with 67 Ga-Citrate, Journal of Nuclear Medicine Technology, issue.4, pp.31-196, 2003.

M. T. Ercan, 99mTc-citrate versus 67Ga-citrate for the scintigraphic visualization of inflammatory lesions, Nuclear Medicine and Biology, vol.20, issue.7, pp.881-887, 1993.
DOI : 10.1016/0969-8051(93)90155-N

C. Nanni, 68 Ga-Citrate PET/CT for Evaluating Patients with Infections of the Bone: Preliminary Results, Journal of Nuclear Medicine, issue.12, pp.51-1932, 2010.

S. J. Goldsmith and S. Vallabhajosula, Clinically Proven Radiopharmaceuticals for Infection Imaging: Mechanisms and Applications. Seminars in nuclear medicine, pp.2-10, 2009.
DOI : 10.1053/j.semnuclmed.2008.08.002

S. Liu, D. S. Edwards-smith-jones, and P. M. , 99m Tc-Labeled Small Peptides as Diagnostic Radiopharmaceuticals Synthesis, biodistribution and renal handling of various chelate-somatostatin conjugates with metabolizable linking groups, Chemical Reviews Nuclear Medicine and Biology, vol.99, issue.778, pp.2235-2268, 1997.

R. K. Hom and J. A. Katzenellenbogen, Technetium-99m-labeled receptor-specific small-molecule radiopharmaceuticals: Recent developments and encouraging results, Nuclear Medicine and Biology, vol.24, issue.6, pp.24-485, 1997.
DOI : 10.1016/S0969-8051(97)00066-8

J. B. Arterburn, Synthesis of 17-!-Substituted Estradiol-Pyridin-2-yl Hydrazine Conjugates as Effective Ligands for Labeling with Alberto's Complex fac[Re(OH 2 ) 3 (CO) 3 ] + in Water, The Journal of Organic Chemistry, issue.18, pp.68-7063, 2003.

M. J. Welch, J. B. Downer, J. A. Katzenellenbogen, and S. , Current Directions in Radiopharmaceutical Research and Development Rhenium Carbonyl Complexes of .beta.-Estradiol Derivatives with High Affinity for the Estradiol Receptor: An Approach to Selective Organometallic Radiopharmaceuticals, Journal of the American Chemical Society, issue.32, pp.117-8372, 1995.

P. C. Meltzer, A Technetium-99m SPECT Imaging Agent Which Targets the Dopamine Transporter in Primate Brain, Journal of Medicinal Chemistry, vol.40, issue.12, pp.40-1835, 1997.
DOI : 10.1021/jm960868t

H. F. Kung, Imaging of dopamine transporters in humans with technetium-99m TRODAT 1, European Journal of Nuclear Medicine, vol.30, issue.11, pp.23-1527, 1996.
DOI : 10.1007/BF01254479

A. R. Fritzberg, Specific and stable labeling of antibodies with technetium-99m with a diamide dithiolate chelating agent., Proceedings of the National Academy of Sciences, pp.85-4025, 1988.
DOI : 10.1073/pnas.85.11.4025

H. Jin and J. Varner, Integrins: roles in cancer development and as treatment targets, British Journal of Cancer, vol.90, issue.3
DOI : 10.1038/sj.bjc.6601576

R. Haubner, 3 -integrin imaging: a new approach to characterise angiogenesis?, European Journal of Nuclear Medicine and Molecular Imaging, issue.0, pp.33-54, 2006.

T. Tran, Tc to Tumor-Targeting Affibody Molecules, Bioconjugate Chemistry, vol.18, issue.2, pp.549-558, 2007.
DOI : 10.1021/bc060291m

X. Chen, Pegylated Arg-Gly-Asp Peptide: 64 Cu Labeling and PET Imaging of Brain Tumor ! v " 3 -Integrin Expression, J Nucl Med, issue.10, pp.45-1776, 2004.

D. Psimadas, Study of the labeling of two novel RGD-peptidic derivatives with the precursor [99mTc(H2O)3(CO)3]+ and evaluation for early angiogenesis detection in cancer, Applied Radiation and Isotopes, vol.64, issue.2, pp.151-159, 2006.
DOI : 10.1016/j.apradiso.2005.06.010

H. R. Maecke and J. C. Reubi, Somatostatin Receptors as Targets for Nuclear Medicine Imaging and Radionuclide Treatment, Journal of Nuclear Medicine, vol.52, issue.6, pp.841-844, 2011.
DOI : 10.2967/jnumed.110.084236

E. B. Silberstein, Radionuclides and Radiopharmaceuticals for 2005, J Nucl Med, vol.46, issue.5, pp.13-14, 2005.

F. A. Jonge and E. K. Pauwels, Technetium, the missing element, European Journal of Nuclear Medicine, vol.22, issue.3, pp.336-344, 1996.
DOI : 10.1007/BF00837634

C. Perrier and E. Segré, Radioactive Isotopes of Element 43, Nature, vol.140, issue.3535, p.193, 1937.
DOI : 10.1038/140193b0

C. Perrier and E. Segré, Technetium: The Element of Atomic Number 43, Nature, vol.159, issue.4027, p.24, 1947.
DOI : 10.1038/159024a0

Z. B. Alfassi, On the ???artificial??? nature of Tc and the ???carrier-free??? nature of 99mTc from 99Mo/99mTc generators, Applied Radiation and Isotopes, vol.63, issue.1, pp.37-40, 2005.
DOI : 10.1016/j.apradiso.2005.01.009

A. Hammermaier, E. Reich, and W. Bögl, Chemical, radiochemical, and radionuclide purity of eluates from different commercial fission99Mo/99mTc generators, European Journal of Nuclear Medicine, vol.138, issue.1, pp.41-46, 1986.
DOI : 10.1007/BF00638794

P. W. Moore, Technetium-99 in Generator Systems, J Nucl Med, vol.25, issue.4, pp.499-502, 1984.

J. C. Hung, Generator eluate effects on the labeling efficiency of 99mTc-sestamibi, Nuclear Medicine and Biology, vol.22, issue.7, pp.949-951, 1995.
DOI : 10.1016/0969-8051(95)94366-L

R. Nickles, Technetium-94m-Tboroxime: Synthesis, Dosimetry, and Initial PET Imaging Studies, Journal of Nuclear Medicine, vol.34, issue.7, pp.1058-1066, 1993.

C. Stone, Technetium 94m-labeled methoxyisobutyl isonitrile: Dosimetry and resting cardiac imaging with positron emission tomography, Journal of Nuclear Cardiology, vol.21, issue.5, pp.425-433, 1994.
DOI : 10.1007/BF02961596

C. P. Casey and O. Chemistry, Organorhenium Chemistry, Science, vol.259, issue.5101, pp.1552-1558, 1993.
DOI : 10.1126/science.259.5101.1552

A. M. Al-ajlouni and J. H. Espenson, Epoxidation of Styrenes by Hydrogen Peroxide As Catalyzed by Methylrhenium Trioxide, Journal of the American Chemical Society, vol.117, issue.36, pp.117-9243, 1995.
DOI : 10.1021/ja00141a016

J. Wassenaar and J. N. Reek, Asymmetric Hydrogenation of Enamides, ??-Enol and ??-Enamido Ester Phosphonates Catalyzed by IndolPhos-Rh Complexes, The Journal of Organic Chemistry, vol.74, issue.21, pp.74-8403, 2009.
DOI : 10.1021/jo9018683

Y. Kuninobu, Rhenium-Catalyzed Regio-and Stereoselective Addition of Two Carbon Units to Terminal Alkynes via Carbon?Carbon Bond Cleavage of "-Keto Sulfones, Organic Letters, issue.11, pp.13-2959, 2011.

V. Lewington, Targeted radionuclide therapy for bone metastases, European Journal of Nuclear Medicine, vol.32, issue.2, pp.66-74, 1993.
DOI : 10.1007/BF02261248

R. Alberto, Metal carbonyl syntheses XXII. Low pressure carbonylation of [MOCl 4 ] -and [MO 4 ] -: the technetium(I) and rhenium(I) complexes, Journal of Organometallic Chemistry, vol.3, issue.49312, pp.119-127, 1995.

R. Schibli, Structural and 99Tc NMR Investigations of Complexes with fac[Tc(CO ) 3 ]+ Moieties and Macrocyclic Thioethers of Various Ring Sizes:# Synthesis and X-ray Structure of the Complexes fac-[Tc(9-ane-S3)(CO) 3 ]Br, fac, Tc 2 (tosylate) 2 (18-ane-S6)(CO) 6 ], and fac-[Tc 2 (20-ane-S6-OH)(CO) 6 ][tosylate] 2 . Inorganic Chemistry, pp.37-3509, 1998.

R. Schibli, Influence of the Denticity of Ligand Systems on the in Vitro and in Vivo Behavior of 99m Tc(I)$%&'()&*+, Functionalization of Biomolecules. Bioconjugate Chemistry, vol.3, issue.7 89 93, pp.11-345, 2000.

R. Schibli, and Synthesis of Tailor-Made Bifunctional Ligand Systems, Bioconjugate Chemistry, vol.13, issue.4, pp.750-756, 2002.
DOI : 10.1021/bc015568r

R. Alberto and R. Motterlini, Chemistry and biological activities of CO-releasing molecules (CORMs) and transition metal complexes, Dalton Transactions, vol.71, issue.17, pp.1651-1660, 2007.
DOI : 10.1039/b701992k

S. S. Jurisson and J. D. Lydon, Potential Technetium Small Molecule Radiopharmaceuticals, Chemical Reviews, vol.99, issue.9, pp.2205-2218, 1999.
DOI : 10.1021/cr980435t

M. J. Abrams, Synthesis and characterization of hexakis(alkyl isocyanide) and hexakis(aryl isocyanide) complexes of technetium(I) Inorganic Chemistry, pp.22-2798, 1983.

M. Aufort, Oxorhenium-Mediated Assembly of Noncyclic Selective Integrin Antagonists: A Combinatorial Approach, ChemBioChem, vol.70, issue.4, pp.583-592, 2011.
DOI : 10.1002/cbic.201000700

E. Wong, Rhenium(V) and Technetium(V) Oxo Complexes of an N 2 N'S Peptidic Chelator:! Evidence of Interconversion between the Syn and Anti Conformations, Inorganic Chemistry, issue.25, pp.36-5799, 1997.

E. Gourni, S Bombesin Derivatives, Journal of Medicinal Chemistry, vol.52, issue.14, pp.52-4234, 2009.
DOI : 10.1021/jm900360d

E. A. Fragogeorgi, S-X-Bombesin[2???14] Derivatives, Bioconjugate Chemistry, vol.20, issue.5, pp.856-867, 2009.
DOI : 10.1021/bc800475k

A. R. Fritzberg, Synthesis and Biological Evaluation of Technetium-99m MAG 3 as a Hippuran Replacement, Journal of Nuclear Medicine, vol.27, issue.1, pp.111-116, 1986.

O. C. Sanchez, 99mTc Complexes with activated ester functions; ligands comprising a 3,4-diamino-benzoate backbone, Nuclear Medicine and Biology, vol.33, issue.3, pp.381-390, 2006.
DOI : 10.1016/j.nucmedbio.2006.01.004

H. P. Vanbilloen, RP-HPLC separation of the diastereomers of technetium-99m labelled tropanes and identity confirmation using radio-LC-MS, Journal of Pharmaceutical and Biomedical Analysis, vol.32, issue.4-5, pp.4-5, 2003.
DOI : 10.1016/S0731-7085(03)00173-0

Z. Zhu, A novel and simplified route to the synthesis of N 3 S chelators for 99m Tc labeling, Nuclear Medicine and Biology, issue.6, pp.28-703, 2001.

G. Liu, -Conjugated Morpholino Oligomers, Bioconjugate Chemistry, vol.13, issue.4, pp.893-897, 2002.
DOI : 10.1021/bc0255384
URL : https://hal.archives-ouvertes.fr/tel-00259428

S. M. Okarvi, Synthesis, radiolabeling and in vitro and in vivo characterization of a technetium-99m-labeled alpha-M2 peptide as a tumor imaging agent, Journal of Peptide Research, vol.63, issue.6, pp.63-460, 2004.
DOI : 10.1111/j.1399-3011.2004.00160.x

D. Blok, New chelation strategy allows for quick and clean 99m Tc-labeling of synthetic peptides, Nuclear Medicine and Biology, issue.6, pp.31-815, 2004.

M. V. Cantorias, MO Tripeptide Diastereomers (M = 99/99m Tc, Re):! Models To Identify the Structure of 99m Tc Peptide Targeted Radiopharmaceuticals, Inorganic Chemistry, issue.18, pp.46-7326, 2007.

K. E. Baidoo, Design, Synthesis, and Initial Evaluation of High-Affinity Technetium Bombesin Analogues, Bioconjugate Chemistry, vol.9, issue.2, pp.218-225, 1998.
DOI : 10.1021/bc9701959

R. W. Weber, Enhanced kidney clearance with an ester-linked 99m Tcradiolabeled antibody Fab'-chelator conjugate, Bioconjugate Chemistry, issue.16, pp.431-437, 1990.
DOI : 10.1021/bc00006a010

H. P. Vanbilloen, Complexes of technetium-99m with tetrapeptides, a new class of 99mTc-labelled agents, Nuclear Medicine and Biology, vol.22, issue.3, pp.325-338, 1995.
DOI : 10.1016/0969-8051(94)00110-6

J. E. Cyr, Technetium(V) Oxo Complexes of Substituted Propylene Diamine Dioxime (PnAO) Ligands:?? Water-Dependent Interconversion between Syn and Anti Isomers, Inorganic Chemistry, vol.40, issue.14, pp.40-3555, 2001.
DOI : 10.1021/ic991381o

L. Gal and J. , Design and synthesis of a novel family of semi-rigid ligands: versatile compounds for the preparation of 99m Tc radiopharmaceuticals, Organic & Biomolecular Chemistry, issue.26, pp.876-883, 2004.

D. J. Canney, Dicarboxylate diamide dimercaptide (N2S2) technetium-99m complexes: synthesis and biological evaluation as potential renal radiopharmaceuticals, Journal of Medicinal Chemistry, vol.36, issue.8, pp.36-1032, 1993.
DOI : 10.1021/jm00060a011

M. Aufort, Chimiothèques de complexe du technétium et du rhénium ciblant l'intégrine ! V " 3 : développement de traceurs pour la détection précoce de la néoangiogenèse tumorale, Thèse de Doctorat, 2008.

R. Rajagopalan, S Ligands, Bioconjugate Chemistry, vol.8, issue.3, pp.407-415, 1997.
DOI : 10.1021/bc9700401

B. A. Nock, Glutathione-Mediated Metabolism of Technetium-99m SNS/S Mixed Ligand Complexes:?? A Proposed Mechanism of Brain Retention, Journal of Medicinal Chemistry, vol.42, issue.6, pp.1066-1075, 1999.
DOI : 10.1021/jm980174f

R. D. Neirinckx, The Retention Mechanism of Technetium-99m-HM-PAO: Intracellular Reaction with Glutathione, Journal of Cerebral Blood Flow & Metabolism, vol.5, issue.1_suppl, pp.4-12, 1988.
DOI : 10.1016/0003-9861(59)90090-6

A. R. Timerbaev, Interactions of Antitumor Metallodrugs with Serum Proteins:?? Advances in Characterization Using Modern Analytical Methodology, Chemical Reviews, vol.106, issue.6, pp.2224-2248, 2006.
DOI : 10.1021/cr040704h

D. K. Hughes, Nuclear Medicine and Infection Detection: The Relative Effectiveness of Imaging with 111 In-Oxine-, 99m Tc-HMPAO-, and 99m Tc-Stannous Fluoride Colloid- Labeled Leukocytes and with 67 Ga-Citrate, Journal of Nuclear Medicine Technology, issue.4, pp.31-196, 2003.

F. Kratz, Albumin as a drug carrier: Design of prodrugs, drug conjugates and nanoparticles, Journal of Controlled Release, vol.132, issue.3, pp.171-183, 2008.
DOI : 10.1016/j.jconrel.2008.05.010

S. T. Wu, A strategy for liquid chromatography/tandem mass spectrometry based quantitation of pegylated protein drugs in plasma using plasma protein precipitation with water-miscible organic solvents and subsequent trypsin digestion to generate surrogate peptides for detection, Rapid Communications in Mass Spectrometry, issue.2, pp.25-281, 2011.

J. Ma, Comparison of ethanol plasma-protein precipitation with plasma ultrafiltration and trichloroacetic acid protein precipitation for the measurement of unbound platinum concentrations, Cancer Chemotherapy and Pharmacology, vol.38, issue.4, pp.391-394, 1996.
DOI : 10.1007/s002800050501

L. C. Marney, Isopropanol Protein Precipitation for the Analysis of Plasma Free Metanephrines by Liquid Chromatography-Tandem Mass Spectrometry, Clinical Chemistry, vol.54, issue.10, pp.54-1729, 2008.
DOI : 10.1373/clinchem.2008.104083

T. Sivaraman, The Mechanism of 2,2,2-Trichloroacetic Acid-Induced Protein Precipitation, Journal of Protein Chemistry, vol.16, issue.04, pp.291-297, 1997.
DOI : 10.1023/A:1026357009886

S. Sengupta, Albumin Thiolate Anion Is an Intermediate in the Formation of Albumin-S-S-Homocysteine, Journal of Biological Chemistry, vol.276, issue.32, pp.276-30111, 2001.
DOI : 10.1074/jbc.M104324200

A. Pastore, Determination of Blood Total, Reduced, and Oxidized Glutathione in Pediatric Subjects, Clin Chem, issue.8, pp.47-1467, 2001.

M. Samuelsson, L. Vainikka, and K. Öllinger, Glutathione in the blood and cerebrospinal fluid: A study in healthy male volunteers, Neuropeptides, vol.45, issue.4, pp.287-292, 2011.
DOI : 10.1016/j.npep.2011.05.004

L. Gal, J. Íková, P. , and Z. Glatz, Nouveaux radiopharmaceutiques de 99m Tc: de la conception à l'évaluation biologique Specific determination of cysteine in human urine by capillary micellar electrokinetic chromatography, Thèse de doctorat, pp.26-734, 2003.

M. A. Stalteri, Comparison of the Stability of Technetium-Labeled Peptides to Challenge with Cysteine, Bioconjugate Chemistry, vol.10, issue.1, pp.130-136, 1998.
DOI : 10.1021/bc9800466

C. Clavaud, Dynamic Combinatorial Self???Assembly of Cyclophilin hCyp???18 Ligands through Oxorhenium Coordination, ChemBioChem, vol.27, issue.11, pp.1823-1829, 2008.
DOI : 10.1002/cbic.200800187

M. Rafii, High-throughput and simultaneous measurement of homocysteine and cysteine in human plasma and urine by liquid chromatography???electrospray tandem mass spectrometry, Analytical Biochemistry, vol.371, issue.1, pp.71-81, 2007.
DOI : 10.1016/j.ab.2007.07.026

C. Clavaud, Combinatorial Self-Assembly of Cyclophilin hCyp-18 Ligands through Rhenium Coordination, ChemBioChem, vol.97, issue.9, pp.1352-1355, 2006.
DOI : 10.1002/cbic.200600204

R. Syhre, Stability versus reactivity of ???3+1" mixed-ligand technetium-99m complexes in vitro and in vivo, European Journal of Nuclear Medicine and Molecular Imaging, vol.25, issue.7, pp.25-793, 1998.
DOI : 10.1007/s002590050284

M. R. , P. R. Carroll, and L. Klotz, Active Surveillance for Prostate Cancer: Progress and Promise, IV.6. Références bibliographiques 1. Cooperberg, 2011.

Y. H. Shao, The impact of PSA testing frequency on prostate cancer incidence and treatment in older men, Prostate Cancer and Prostatic Diseases, vol.149, issue.4, 2011.
DOI : 10.1001/jama.2009.1348

C. Evans, Neonatal plasma TSH ??? estimated upper reference intervals for diagnosis and follow up of congenital hypothyroidism, Scandinavian Journal of Clinical and Laboratory Investigation, vol.44, issue.5, pp.71-394, 2011.
DOI : 10.3109/00365513.2011.575234

E. Molinaro, Recombinant human TSH (rhTSH) in 2009: new perspectives in diagnosis and therapy, Quarterly Journal of Nuclear Medicine and Molecular Imaging, vol.53, issue.5, pp.490-502, 2009.

J. Al-shuneigat, S. Mahgoub, and F. Huq, Colorectal carcinoma: nucleosomes, carcinoembryonic antigen and ca 19-9 as apoptotic markers; a comparative study, Journal of Biomedical Science, vol.18, issue.1, p.50, 2011.
DOI : 10.1159/000094694

G. P. González, I-Labeled Anticarcinoembryonic Antigen CIGB-M3 Multivalent Antibody Fragment, Cancer Biotherapy & Radiopharmaceuticals, vol.26, issue.3, pp.353-363, 2011.
DOI : 10.1089/cbr.2010.0899

A. Radu, Expression of Follicle-Stimulating Hormone Receptor in Tumor Blood Vessels, New England Journal of Medicine, issue.17, pp.363-1621, 2010.

J. García-román, VEGF secretion during hypoxia depends on free radicals-induced Fyn kinase activity in mast cells, Biochemical and Biophysical Research Communications, vol.401, issue.2, pp.262-267, 2010.
DOI : 10.1016/j.bbrc.2010.09.047

M. Egger, Hypoxia up-regulates the angiogenic cytokine secretoneurin via an HIF-1??- and basic FGF-dependent pathway in muscle cells, The FASEB Journal, vol.21, issue.11, pp.2906-2917, 2007.
DOI : 10.1096/fj.06-7440com

P. Vaupel and L. Harrison, Tumor Hypoxia: Causative Factors, Compensatory Mechanisms, and Cellular Response, The Oncologist, vol.9, issue.suppl_5, pp.4-9, 2004.
DOI : 10.1634/theoncologist.9-90005-4

P. Brooks, R. Clark, and D. Cheresh, Requirement of vascular integrin alpha v beta 3 for angiogenesis, Science, vol.264, issue.5158, pp.569-571, 1994.
DOI : 10.1126/science.7512751

J. Xiong, Crystal Structure of the Extracellular Segment of Integrin ! v " 3, Science, issue.5541, pp.294-339, 2001.

J. S. Bennett, Structure and function of the platelet integrin ??IIb??3, Journal of Clinical Investigation, vol.115, issue.12, pp.3363-3369, 2005.
DOI : 10.1172/JCI26989

F. Ye, C. Kim, and M. H. Ginsberg, Molecular mechanism of inside-out integrin regulation, Journal of Thrombosis and Haemostasis, vol.34, issue.9, pp.20-25, 2011.
DOI : 10.1111/j.1538-7836.2011.04355.x

F. G. Giancotti, E. Ruoslahti, and I. Signaling, Integrin Signaling, Science, vol.285, issue.5430, pp.1028-1033, 1999.
DOI : 10.1126/science.285.5430.1028

C. Mas-moruno, F. Rechenmacher, and H. Kessler, Cilengitide: The First Anti-Angiogenic Small Molecule Drug Candidate. Design, Synthesis and Clinical Evaluation, Anti-Cancer Agents in Medicinal Chemistry, vol.10, issue.10
DOI : 10.2174/187152010794728639

S. Frisch and H. Francis, Disruption of epithelial cell-matrix interactions induces apoptosis, The Journal of Cell Biology, vol.124, issue.4, pp.619-626, 1994.
DOI : 10.1083/jcb.124.4.619

B. Felding-habermann, Involvement of tumor cell integrin ! v " 3 in hematogenous metastasis of human melanoma cells, Clinical and Experimental Metastasis, vol.19, issue.5, pp.427-436, 2002.
DOI : 10.1023/A:1016377114119

P. Clezardin, Recent insights into the role of integrins in cancer metastasis, Cellular and Molecular Life Sciences (CMLS), vol.54, issue.6, pp.541-548, 1998.
DOI : 10.1007/s000180050182

A. Huttenlocher, R. Sandborg, and A. Horwitz, Adhesion in cell migration, Current Opinion in Cell Biology, vol.7, issue.5, pp.697-706, 1995.
DOI : 10.1016/0955-0674(95)80112-X

J. T. Yang, H. Rayburn, and R. O. Hynes, Cell adhesion events mediated by alpha 4 integrins are essential in placental and cardiac development, Development, vol.121, issue.2, pp.549-560, 1995.

B. P. Eliceiri and D. A. Cheresh, The role of ??v integrins during angiogenesis: insights into potential mechanisms of action and clinical development, Journal of Clinical Investigation, vol.103, issue.9, pp.1227-1230, 1999.
DOI : 10.1172/JCI6869

L. E. Reynolds, Enhanced pathological angiogenesis in mice lacking ??3 integrin or ??3 and ??5 integrins, Nature Medicine, vol.8, issue.1, pp.27-34, 2002.
DOI : 10.1038/nm0102-27

G. Mizejewski, Role of Integrins in Cancer: Survey of Expression Patterns, Proceedings of the society for experimental biology and medicine, pp.124-138, 1999.
DOI : 10.1046/j.1525-1373.1999.d01-122.x

W. L. Rust, S. W. Carper, and G. E. Plopper, The Promise of Integrins as Effective Targets for Anticancer Agents, Journal of Biomedicine and Biotechnology, vol.2, issue.3, pp.124-130, 2002.
DOI : 10.1155/S1110724302204015

H. Jin and J. Varner, Integrins: roles in cancer development and as treatment targets, British Journal of Cancer, vol.90, issue.3
DOI : 10.1038/sj.bjc.6601576

R. Haubner, v ! 3 -integrin imaging: a new approach to characterise angiogenesis?, European Journal of Nuclear Medicine and Molecular Imaging, issue.0, pp.33-54, 2006.

A. Matter, Tumor angiogenesis as a therapeutic target, Drug Discovery Today, vol.6, issue.19, pp.1005-1024, 2001.
DOI : 10.1016/S1359-6446(01)01939-0

M. G. Berry, Integrin expression and survival in human breast cancer, European Journal of Surgical Oncology (EJSO), vol.30, issue.5, pp.484-489, 2004.
DOI : 10.1016/j.ejso.2004.01.016

A. Vonlaufen, Integrin ??v??3 Expression in Colon Carcinoma Correlates with Survival, Modern Pathology, vol.14, issue.11, pp.1126-1132, 2001.
DOI : 10.1038/modpathol.3880447

E. Ruoslahti, The RGD story: a personal account, Matrix Biology, vol.22, issue.6, pp.459-465, 2003.
DOI : 10.1016/S0945-053X(03)00083-0

J. Xiong, Crystal Structure of the Extracellular Segment of Integrin alpha Vbeta 3 in Complex with an Arg-Gly-Asp Ligand, Science, vol.296, issue.5565, pp.296-151, 2002.
DOI : 10.1126/science.1069040

A. Corti and F. Curnis, Isoaspartate-dependent molecular switches for integrin-ligand recognition, Journal of Cell Science, vol.124, issue.4, pp.515-522, 2011.
DOI : 10.1242/jcs.077172

G. Niu and X. Chen, Why Integrin as a Primary Target for Imaging and Therapy, Theranostics, vol.1, issue.1, pp.30-47, 2011.
DOI : 10.7150/thno/v01p0030

D. Heckmann, Breaking the Dogma of the Metal-Coordinating Carboxylate Group in Integrin Ligands: Introducing Hydroxamic Acids to the MIDAS To Tune Potency and Selectivity, Angewandte Chemie International Edition, vol.77, issue.24, pp.48-4436, 2009.
DOI : 10.1002/anie.200900206

J. Shiu, Solution structure of ??-bungarotoxin: The functional significance of amino acid residues flanking the RGD motif in integrin binding, Proteins: Structure, Function, and Bioinformatics, vol.8, issue.4, pp.839-849, 2004.
DOI : 10.1002/prot.20269

B. Cacciari and G. Spalluto, Non Peptidic αvβ3 Antagonists: Recent Developments, Current Medicinal Chemistry, vol.12, issue.1, pp.51-70, 2005.
DOI : 10.2174/0929867053363522

R. Stupp, Phase I/IIa Study of Cilengitide and Temozolomide With Concomitant Radiotherapy Followed by Cilengitide and Temozolomide Maintenance Therapy in Patients With Newly Diagnosed Glioblastoma, Journal of Clinical Oncology, vol.28, issue.16, pp.28-2712, 2010.
DOI : 10.1200/JCO.2009.26.6650

J. B. Vermorken, Phase I/II trial of cilengitide with cetuximab, cisplatin and 5-fluorouracil in recurrent and/or metastatic squamous cell cancer of the head and neck: findings of the phase I part, British Journal of Cancer, vol.9, issue.11, pp.104-1691, 2011.
DOI : 10.1056/NEJMoa0802656

Y. Chen, LYG-202, a Newly Synthesized Flavonoid, Exhibits Potent Anti-angiogenic Activity In Vitro and In Vivo, Journal of Pharmacological Sciences, vol.112, issue.1, pp.37-45, 2010.
DOI : 10.1254/jphs.09213FP

M. Tsai, Anti-angiogenic effect of Tanshinone IIA involves inhibition of matrix invasion and modification of MMP-2/TIMP-2 secretion in vascular endothelial cells. Cancer letters, pp.310-198, 2011.

I. Limam, Leberagin-C, A disintegrin-like/cysteine-rich protein from Macrovipera lebetina transmediterranea venom, inhibits alphavbeta3 integrin-mediated cell adhesion, Matrix Biology, vol.29, issue.2, pp.117-126, 2010.
DOI : 10.1016/j.matbio.2009.09.009
URL : https://hal.archives-ouvertes.fr/pasteur-00621003

W. Wang, Acurhagin-C, an ECD disintegrin, inhibits integrin "v#3-mediated human endothelial cell functions by inducing apoptosis via caspase-3 activation, British Journal of Pharmacology, issue.6, pp.160-1338, 2010.
DOI : 10.1111/j.1476-5381.2010.00781.x
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2938806

R. Haubner, Structural and Functional Aspects of RGD-Containing Cyclic Pentapeptides as Highly Potent and Selective Integrin ! v " 3 Antagonists, Journal of the American Chemical Society, issue.32, pp.118-7461, 1996.

J. Chatterjee, N-Methylation of Peptides: A New Perspective in Medicinal Chemistry, Accounts of Chemical Research, vol.41, issue.10, pp.41-1331, 2008.
DOI : 10.1021/ar8000603

M. A. Dechantsreiter, N-Methylated Cyclic RGD Peptides as Highly Active and Selective ! V " 3 Integrin Antagonists, Journal of Medicinal Chemistry, issue.16, pp.42-3033, 1999.
DOI : 10.1021/jm970832g

T. Taga, ?v-Integrin antagonist EMD 121974 induces apoptosis in brain tumor cells growing on vitronectin and tenascin, International Journal of Cancer, vol.46, issue.87, pp.98-690, 2002.
DOI : 10.1002/ijc.10265

F. A. Eskens, Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins [alpha]v[beta]3 and [alpha]v[beta]5 in patients with advanced solid tumours, European Journal of Cancer, issue.7, pp.39-917, 2003.

M. Gilbert, Cilengitide in patients with recurrent glioblastoma: the results of NABTC 03-02, a phase II trial with measures of treatment delivery, Journal of Neuro-Oncology, vol.11, issue.6, pp.1-7
DOI : 10.1007/s11060-011-0650-1

D. A. Reardon, Randomized Phase II Study of Cilengitide, an Integrin-Targeting Arginine-Glycine-Aspartic Acid Peptide, in Recurrent Glioblastoma Multiforme, Journal of Clinical Oncology, vol.26, issue.34, pp.26-5610, 2008.
DOI : 10.1200/JCO.2008.16.7510

A. Alva, Phase II study of Cilengitide (EMD 121974, NSC 707544) in patients with non-metastatic castration resistant prostate cancer, NCI-6735. A study by the DOD/PCF prostate cancer clinical trials consortium, Investigational New Drugs, vol.7, issue.5, pp.1-9
DOI : 10.1007/s10637-010-9573-5

H. Friess, A randomized multi-center phase II trial of the angiogenesis inhibitor Cilengitide (EMD 121974) and gemcitabine compared with gemcitabine alone in advanced unresectable pancreatic cancer, BMC Cancer, vol.56, issue.1, p.285, 2006.
DOI : 10.1016/S0360-3016(03)00447-4

R. Stupp, promoter methylation: Protocol of a multicenter, randomized, open-label, controlled phase III trial (CENTRIC)., Journal of Clinical Oncology, vol.28, issue.15_suppl, p.15, 2010.
DOI : 10.1200/jco.2010.28.15_suppl.tps152

C. Mas-moruno, Increasing !v"3 Selectivity of the Anti-Angiogenic Drug Cilengitide by N-Methylation, Angewandte Chemie International Edition, 2011.

Y. Zhou, S. Chakraborty, and S. Liu, Radiolabeled Cyclic RGD Peptides as Radiotracers for Imaging Tumors and Thrombosis by SPECT, Theranostics, vol.1, issue.1, pp.2011-58
DOI : 10.7150/thno/v01p0058

F. Zanardi, Discovery of Subnanomolar Arginine-Glycine-Aspartate-Based ! V " 3 /! V " 5 Integrin Binders Embedding 4-Aminoproline Residues, Journal of Medicinal Chemistry, issue.6, pp.51-1771, 2008.

E. Lohof, Carbohydrate Derivatives for Use in Drug Design: Cyclic??v-Selective RGD Peptides, Angewandte Chemie International Edition, vol.39, issue.15, pp.39-2761, 2000.
DOI : 10.1002/1521-3773(20000804)39:15<2761::AID-ANIE2761>3.0.CO;2-9

L. Belvisi, Potent Integrin Antagonists from a Small Library of RGD-Including Cyclic Pseudopeptides, Organic Letters, vol.3, issue.7, pp.1001-1004, 2001.
DOI : 10.1021/ol007049u

L. Belvisi, Targeting integrins: Insights into structure and activity of cyclic RGD pentapeptide mimics containing azabicycloalkane amino acids, Bioorganic & Medicinal Chemistry, vol.14, issue.1, pp.169-180, 2006.
DOI : 10.1016/j.bmc.2005.08.048

J. Schmidt, Cyclization of Peptides through a Urea Bond: Application to the Arg-Gly-Asp Tripeptide, ChemBioChem, vol.8, issue.8, pp.1083-1092, 2010.
DOI : 10.1002/cbic.201000062
URL : https://hal.archives-ouvertes.fr/inserm-00482710

M. Albrecht, Preparation of Tripeptide-Bridged Dicatechol Ligands and Their Macrocyclic Molybdenum(VI) Complexes: Fixation of the RGD Sequence and the WKY Sequence of Urotensin II in a Cyclic Conformation, Chemistry - A European Journal, vol.10, issue.15, pp.10-3657, 2004.
DOI : 10.1002/chem.200400144

L. Marinelli, Docking Studies on !v"3 Integrin Ligands:# Pharmacophore Refinement and Implications for Drug Design, Journal of Medicinal Chemistry, issue.21, pp.46-4393, 2003.

L. Marinelli, Human Integrin ??v??5:?? Homology Modeling and Ligand Binding, Journal of Medicinal Chemistry, vol.47, issue.17, pp.4166-4177, 2004.
DOI : 10.1021/jm030635j

G. A. Sulyok, Solid-Phase Synthesis of a Nonpeptide RGD Mimetic Library:?? New Selective ??v??3 Integrin Antagonists, Journal of Medicinal Chemistry, vol.44, issue.12, pp.44-1938, 2001.
DOI : 10.1021/jm0004953

M. Aufort, Oxorhenium-Mediated Assembly of Noncyclic Selective Integrin Antagonists: A Combinatorial Approach, ChemBioChem, vol.70, issue.4, pp.583-592, 2011.
DOI : 10.1002/cbic.201000700

R. Dayam, Discovery of Small Molecule Integrin ! v " 3 Antagonists as Novel Anticancer Agents, Journal of Medicinal Chemistry, issue.15, pp.49-4526, 2006.

B. Strijtveen and R. Kellogg, Synthesis of (racemization prone) optically active thiols by SN2 substitution using cesium thiocarboxylates, The Journal of Organic Chemistry, vol.51, issue.19, pp.3664-3671, 1986.
DOI : 10.1021/jo00369a020

Y. Cui, Design and synthesis of chromogenic thiopeptolide substrates as MetAPs active site probes, Bioorganic & Medicinal Chemistry, vol.12, issue.11, pp.2853-2861, 2004.
DOI : 10.1016/j.bmc.2004.03.044

E. Balducci, Microwave-Assisted Intramolecular Huisgen Cycloaddition of Azido Alkynes Derived from ??-Amino Acids, The Journal of Organic Chemistry, vol.74, issue.3, pp.1314-1321, 2009.
DOI : 10.1021/jo802463r

F. Kratz, Albumin as a drug carrier: Design of prodrugs, drug conjugates and nanoparticles, Journal of Controlled Release, vol.132, issue.3, pp.171-183, 2008.
DOI : 10.1016/j.jconrel.2008.05.010

M. A. Pilkington-miksa, Synthesis of Bifunctional Integrin-Binding Peptides Containing PEG Spacers of Defined Length for Non-Viral Gene Delivery, European Journal of Organic Chemistry, vol.27, issue.17, pp.2900-2914, 2008.
DOI : 10.1002/ejoc.200701188

M. Schottelius, Ligands for Mapping !v"3-Integrin Expression in Vivo, Accounts of Chemical Research, issue.7, pp.42-969, 2009.

V. Rerat, 3 Integrin-Targeting Arg-Gly-Asp (RGD) Peptidomimetics Containing Oligoethylene Glycol (OEG) Spacers, Journal of Medicinal Chemistry, issue.22, pp.52-7029, 2009.
DOI : 10.1021/jm901133z

A. J. Beer, Biodistribution and Pharmacokinetics of the ! v " 3 -Selective Tracer 18 F-Galacto-RGD in Cancer Patients, Journal of Nuclear Medicine, issue.8, pp.46-1333, 2005.

S. Liu, Targeted Radiotracers for Tumor Imaging, Molecular Pharmaceutics, vol.3, issue.5, pp.472-487, 2006.
DOI : 10.1021/mp060049x

S. Liu, -Targeted Radiotracers: Maximizing Binding Affinity via Bivalency, Bioconjugate Chemistry, vol.20, issue.12, pp.2199-2213, 2009.
DOI : 10.1021/bc900167c
URL : https://hal.archives-ouvertes.fr/tel-00259428

Z. Su, Integrin for Tumor Imaging, Bioconjugate Chemistry, vol.13, issue.3, pp.561-570, 2002.
DOI : 10.1021/bc0155566

D. Boturyn, RAFT Nano-constructs: surfing to biological applications, Journal of Peptide Science, vol.22, issue.2, pp.224-240, 2008.
DOI : 10.1002/psc.964

M. Galibert, Application of click???click chemistry to the synthesis of new multivalent RGD conjugates, Organic & Biomolecular Chemistry, vol.42, issue.22, pp.5133-5138, 2010.
DOI : 10.1039/c0ob00070a
URL : https://hal.archives-ouvertes.fr/inserm-00559554

M. Galibert, RGD???cyclam conjugate: Synthesis and potential application for positron emission tomography, Bioorganic & Medicinal Chemistry Letters, vol.20, issue.18, pp.5422-5425, 2010.
DOI : 10.1016/j.bmcl.2010.07.114

Z. Jin, Noninvasive visualization and quantification of tumor ??V??3 integrin expression using a novel positron emission tomography probe, 64Cu-cyclam-RAFT-c(-RGDfK-)4, Nuclear Medicine and Biology, vol.38, issue.4, pp.529-540, 2011.
DOI : 10.1016/j.nucmedbio.2010.11.008

L. Sancey, In vivo imaging of tumour angiogenesis in mice with the ??v??3 integrin-targeted tracer 99mTc-RAFT-RGD, European Journal of Nuclear Medicine and Molecular Imaging, vol.18, issue.Pt 19, pp.2037-2047, 2007.
DOI : 10.1007/s00259-007-0497-z
URL : https://hal.archives-ouvertes.fr/inserm-00176669

J. Dimastromatteo, In vivo molecular imaging of myocardial angiogenesis using the ??v??3 integrin-targeted tracer 99mTc-RAFT-RGD, Journal of Nuclear Cardiology, vol.290, issue.3, pp.435-443, 2010.
DOI : 10.1007/s12350-010-9191-9

E. Biron, J. Chatterjee, and H. Kessler, Optimized selectiveN-methylation of peptides on solid support, Journal of Peptide Science, vol.35, issue.3, pp.213-219, 2006.
DOI : 10.1002/psc.711

E. Biron and H. Kessler, -Methylamino Acids Compatible with Fmoc Solid-Phase Peptide Synthesis, The Journal of Organic Chemistry, vol.70, issue.13, pp.70-5183, 2005.
DOI : 10.1021/jo050477z
URL : https://hal.archives-ouvertes.fr/halshs-00607826

S. C. Miller and T. S. Scanlan, Site-Selective N-Methylation of Peptides on Solid Support, Journal of the American Chemical Society, vol.119, issue.9, pp.2301-2302, 1997.
DOI : 10.1021/ja9635443

. Une-masse-m, ~5 mg) est pesée, mise en suspension dans V = 10 mL d'un mélange pipéridine/DMF (1/4) et agitée durant 10 minutes à température ambiante. L'absorbance (A) de la solution à 290 nm est alors mesurée

A. Si, la substitution initiale de la résine, M1, la masse moléculaire du groupement partant (g.mol -1 ), et M2 la masse moléculaire du groupement ajouté (g. mol -1 )